How long should valproic acid be discontinued before it is safe to become pregnant?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Valproic Acid Discontinuation Before Pregnancy

Valproic acid should be discontinued and switched to a safer alternative antiepileptic drug (such as lamotrigine, levetiracetam, or oxcarbazepine) as soon as pregnancy is being planned, ideally with folic acid supplementation starting at least 12 weeks before conception. There is no specific "safe waiting period" after stopping valproic acid before attempting pregnancy—the critical issue is ensuring the drug is completely out of your system and replaced with appropriate seizure control before conception occurs.

Key Timing Considerations

Pre-Conception Planning

The FDA drug label emphasizes that valproate should not be administered to a woman of childbearing potential unless the drug is essential to the management of her medical condition 1. The focus is on discontinuation before conception rather than a waiting period after discontinuation, because:

  • Neural tube defects occur very early in pregnancy (within the first 3-4 weeks after conception, often before a woman knows she's pregnant) 1
  • Valproic acid has a relatively short half-life (approximately 9-16 hours), meaning it clears from the body within days, not months
  • The teratogenic risk is from exposure during pregnancy, not from prior use

Folic Acid Supplementation Timeline

High-risk women (including those with prior valproic acid exposure) should take 4,000 μg (4 mg) of folic acid daily starting at least 12 weeks prior to conception, then continue with a reduced dose of 400 μg (0.4 mg) after completing 12 weeks of gestation 2. While folic acid supplementation is recommended, it is not known whether folic acid reduces the risk of neural tube defects or decreased IQ specifically in offspring of women who were previously on valproate 1.

The Critical Risks That Drive This Recommendation

Major Congenital Malformations

Valproic acid exposure during pregnancy carries severe teratogenic risks compared to other antiepileptic drugs:

  • Neural tube defects: 6.54 times higher risk 3
  • Cleft lip/palate: 4.31 times higher risk 3
  • Congenital heart defects: 2.53 times higher risk 3
  • Genitourinary anomalies: 3.32 times higher risk 3
  • Overall major congenital malformations: 2.36 times higher risk 3

Neurodevelopmental Effects

Children exposed to valproate in utero have lower IQ scores (mean 97) compared to other antiepileptic drugs like lamotrigine (108), carbamazepine (105), and phenytoin (108) 1. This cognitive impairment represents permanent disability that cannot be prevented by folic acid supplementation.

Practical Switching Strategy

The Transition Process

When switching from valproic acid to a safer alternative:

  1. Do not abruptly discontinue valproate, as this can precipitate status epilepticus with resulting maternal and fetal hypoxia 1

  2. Initiate the alternative AED first, then gradually taper valproate by approximately 25% every 2 weeks while monitoring seizure control 1

  3. Complete the switch before attempting conception—there is no additional waiting period needed after valproate is fully discontinued

Risk of Seizure Recurrence

Women withdrawn from valproic acid have 1.73 times higher odds of tonic-clonic seizure recurrence during pregnancy compared to those maintained on valproate 4. Between 7.9% and 72.2% of women withdrawn from valproate before or during pregnancy eventually restart it 4. This underscores the importance of:

  • Careful selection of alternative AEDs with adequate seizure control
  • Close monitoring during the transition period
  • Balancing seizure control against teratogenic risk

Common Pitfalls to Avoid

Pitfall #1: Waiting for a "washout period" after stopping valproate. The drug clears quickly; the goal is simply to have it out of your system before conception, not to wait months afterward.

Pitfall #2: Stopping valproate abruptly without transitioning to another AED. This risks life-threatening status epilepticus 1.

Pitfall #3: Assuming folic acid supplementation makes valproate safe during pregnancy. While folic acid is recommended, there is no evidence it eliminates the neurodevelopmental or malformation risks specific to valproate 1.

Pitfall #4: Discovering pregnancy while still on valproate and immediately stopping it. The damage from neural tube defects occurs in the first 3-4 weeks; by the time pregnancy is discovered, this critical period may have passed. The decision to continue or switch must weigh the risk of seizures against ongoing fetal exposure 4.

The Bottom Line for Clinical Practice

Valproate should be avoided entirely in women of childbearing potential unless all other options have failed 1, 5. When pregnancy is planned, switch to lamotrigine, levetiracetam, or oxcarbazepine immediately, start high-dose folic acid (4 mg daily) at least 12 weeks before attempting conception, and ensure effective contraception during the transition period 2, 5. Once valproate is fully discontinued and seizures are controlled on an alternative medication, pregnancy can be safely attempted without any additional waiting period.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.